Asthma is characterized by chronic airway inflammation, which is the underlying cause of airway remodeling featured by goblet cell hyperplasia, subepithelial fibrosis, and proliferation of smooth muscle. Sevoflurane has been used to treat life-threatening asthma and our previous study shows that sevoflurane inhibits acute lung inflammation in ovalbumin (OVA)-induced allergic mice. However, the effect of sevoflurane on airway remodeling in the context of chronic airway inflammation and the underlying mechanism are still unknown. Here, female C57BL/6 mice were used to establish chronic airway inflammation model. Hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Sirius red (SR) staining were used to evaluate airway remodeling. Protein levels of α-SMA, VEGF, and TGF-β1 in lung tissues were detected by western blotting analyses and immunohistochemistry staining. Results showed that inhalation of sevoflurane inhibited chronic airway inflammation including inflammatory cell infiltration and pro-inflammatory cytokine production in BALF of the OVA-challenged mice. Meanwhile, sevoflurane suppressed airway thickening, goblet cell hyperplasia, smooth muscle hyperplasia, collagen deposition, and fiber hyperplasia in the lung tissues of the mice with airway remodeling. Most notably, sevoflurane inhibited the OVA-induced expressions of VEGF and TGF-β1. These results suggested that sevoflurane effectively inhibits airway remodeling in mouse model of chronic airway inflammation, which may be due to the downregulation of VEGF and TGF-β1in lung tissues. Therefore, our results indicate a potential role of sevoflurane in inhibiting airway remodeling besides its known suppression effect on airway inflammation, and support the use of sevoflurane in treating severe asthma in ICU.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Galli, S.J., M. Tsai, and A.M. Piliponsky. 2008. The development of allergic inflammation. Nature 454 (7203): 445–454.
Girodet, P.O., A. Ozier, I. Bara, J.M. Tunon de Lara, R. Marthan, and P. Berger. 2011. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacology & Therapeutics 130 (3): 325–337.
Trejo Bittar, H.E., S.A. Yousem, and S.E. Wenzel. 2015. Pathobiology of severe asthma. Annual Review of Pathology 10: 511–545.
Durrani, S.R., R.K. Viswanathan, and W.W. Busse. 2011. What effect does asthma treatment have on airway remodeling? Current perspectives. The Journal of Allergy and Clinical Immunology 128 (3): 439–448 quiz 449-450.
Doherty, T.A., P. Soroosh, N. Khorram, S. Fukuyama, P. Rosenthal, J.Y. Cho, P.S. Norris, H. Choi, S. Scheu, K. Pfeffer, B.L. Zuraw, C.F. Ware, D.H. Broide, and M. Croft. 2011. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nature Medicine 17 (5): 596–603.
Robinson, C.B., J. Leonard, and R.A. Panettieri Jr. 2012. Drug development for severe asthma: what are the metrics? Pharmacology & Therapeutics 135 (2): 176–181.
Leatherman, J. 2015. Mechanical ventilation for severe asthma. Chest 147 (6): 1671–1680.
Louie, S., B.M. Morrissey, N.J. Kenyon, T.E. Albertson, and M. Avdalovic. 2012. The critically ill asthmatic--from ICU to discharge. Clinical Reviews in Allergy and Immunology 43 (1–2): 30–44.
Carrie, S., and T.A. Anderson. 2015. Volatile anesthetics for status asthmaticus in pediatric patients: a comprehensive review and case series. Paediatric Anaesthesia 25 (5): 460–467.
Watanabe, K., T. Mizutani, S. Yamashita, Y. Tatekawa, T. Jinbo, and M. Tanaka. 2008. Prolonged sevoflurane inhalation therapy for status asthmaticus in an infant. Paediatric Anaesthesia 18 (6): 543–545.
Weber, T., C. Schiebenpflug, and E. Deusch. 2012. Inhalational sevoflurane in severe bronchial obstruction unresponsive to multipharmacologic therapy: a case report. F1000Res 1: 56.
Schultz, T.E. 2005. Sevoflurane administration in status asthmaticus: a case report. AANA Journal 73 (1): 35–36.
Lin, T.Y., N. Venkatesan, M. Nishioka, S. Kyoh, L. Al-Alwan, C.J. Baglole, D.H. Eidelman, M.S. Ludwig, and Q. Hamid. 2014. Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells. Clinical and Experimental Allergy 44 (11): 1347–1360.
Royce, S.G., Y. Moodley, and C.S. Samuel. 2014. Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. Pharmacology & Therapeutics 141 (3): 250–260.
Burburan, S.M., J.D. Silva, S.C. Abreu, C.S. Samary, I.H. Guimaraes, D.G. Xisto, M.M. Morales, and P.R. Rocco. 2014. Effects of inhalational anaesthetics in experimental allergic asthma. Anaesthesia 69 (6): 573–582.
Shen, Q.Y., L. Fang, H.M. Wu, F. He, P.S. Ding, and R.Y. Liu. 2015. Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. Respirology 20 (2): 258–263.
Doherty, T., and D. Broide. 2007. Cytokines and growth factors in airway remodeling in asthma. Current Opinion in Immunology 19 (6): 676–680.
Ricciardolo, F.L., F. Sabatini, V. Sorbello, S. Benedetto, I. Defilippi, L. Petecchia, C. Usai, et al. 2013. Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD. Thorax 68 (9): 803–811.
Wisniewski, J.A., and L. Borish. 2011. Novel cytokines and cytokine-producing T cells in allergic disorders. Allergy and Asthma Proceedings 32 (2): 83–94.
Keglowich, L.F., and P. Borger. 2015. The three A’s in asthma - airway smooth muscle, airway remodeling & angiogenesis. Open Respiratory Medicine Journal 9: 70–80.
Kumar, R.K., C. Herbert, and P.S. Foster. 2008. The “classical” ovalbumin challenge model of asthma in mice. Current Drug Targets 9 (6): 485–494.
Wu, H.M., Q.Y. Shen, L. Fang, S.H. Zhang, P.T. Shen, Y.J. Liu, and R.Y. Liu. 2016. JNK-TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis. Journal of Pineal Research 60 (4): 415–423.
Lopez-Guisa, J.M., C. Powers, D. File, E. Cochrane, N. Jimenez, and J.S. Debley. 2012. Airway epithelial cells from asthmatic children differentially express proremodeling factors. The Journal of Allergy and Clinical Immunology 129 (4): 990–997 e996.
Yuksel, H., O. Yilmaz, M. Karaman, H.A. Bagriyanik, F. Firinci, M. Kiray, A. Turkeli, and O. Karaman. 2013. Role of vascular endothelial growth factor antagonism on airway remodeling in asthma. Annals of Allergy, Asthma & Immunology 110 (3): 150–155.
Wang, N., D. Yan, Y. Liu, X. Gu, J. Sun, F. Long, and S. Jiang. 2016. A HuR/TGF-beta1 feedback circuit regulates airway remodeling in airway smooth muscle cells. Respiratory Research 17 (1): 117.
Puig, N.R., P. Ferrero, M.L. Bay, G. Hidalgo, J. Valenti, N. Amerio, and G. Elena. 2002. Effects of sevoflurane general anesthesia: immunological studies in mice. International Immunopharmacology 2 (1): 95–104.
Burburan, S.M., D.G. Xisto, H.C. Ferreira, R. Riva Ddos, G.M. Carvalho, W.A. Zin, and P.R. Rocco. 2007. Lung mechanics and histology during sevoflurane anesthesia in a model of chronic allergic asthma. Anesthesia and Analgesia 104 (3): 631–637.
Wicks, J., H.M. Haitchi, S.T. Holgate, D.E. Davies, and R.M. Powell. 2006. Enhanced upregulation of smooth muscle related transcripts by TGF beta2 in asthmatic (myo) fibroblasts. Thorax 61 (4): 313–319.
Ierodiakonou, D., D.S. Postma, G.H. Koppelman, J. Gerritsen, N.H. ten Hacken, W. Timens, H.M. Boezen, and J.M. Vonk. 2013. TGF-beta1 polymorphisms and asthma severity, airway inflammation, and remodeling. The Journal of Allergy and Clinical Immunology 131 (2): 582–585.
Bakakos, P., G. Patentalakis, and A. Papi. 2016. Vascular biomarkers in asthma and COPD. Current Topics in Medicinal Chemistry 16 (14): 1599–1609.
Yang, Y.C., N. Zhang, K. Van Crombruggen, G.H. Hu, S.L. Hong, and C. Bachert. 2012. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy 67 (10): 1193–1202.
Rogerio, A.P., C. Fontanari, E. Borducchi, A.C. Keller, M. Russo, E.G. Soares, D.A. Albuquerque, and L.H. Faccioli. 2008. Anti-inflammatory effects of Lafoensia pacari and ellagic acid in a murine model of asthma. European Journal of Pharmacology 580 (1–2): 262–270.
Bordon, Y. 2013. Asthma and allergy: TGFbeta--too much of a good thing? Nature Reviews. Immunology 13 (9): 618–619.
Liu, Y.N., W.J. Zha, Y. Ma, F.F. Chen, W. Zhu, A. Ge, X.N. Zeng, and M. Huang. 2015. Galangin attenuates airway remodelling by inhibiting TGF-beta1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. Scientific Reports 5: 11758.
Firszt, R., D. Francisco, T.D. Church, J.M. Thomas, J.L. Ingram, and M. Kraft. 2014. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-beta1 in airway fibroblasts in asthma. The European Respiratory Journal 43 (2): 464–473.
Minagawa, S., J. Lou, R.I. Seed, A. Cormier, S. Wu, Y. Cheng, L. Murray, et al. 2014. Selective targeting of TGF-beta activation to treat fibroinflammatory airway disease. Science Translational Medicine 6 (241): 241ra279.
Ribatti, D., I. Puxeddu, E. Crivellato, B. Nico, A. Vacca, and F. Levi-Schaffer. 2009. Angiogenesis in asthma. Clinical and Experimental Allergy 39 (12): 1815–1821.
Harkness, L.M., A.W. Ashton, and J.K. Burgess. 2015. Asthma is not only an airway disease, but also a vascular disease. Pharmacology & Therapeutics 148: 17–33.
Takyar, S., H. Vasavada, J.G. Zhang, F. Ahangari, N. Niu, Q. Liu, C.G. Lee, L. Cohn, and J.A. Elias. 2013. VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis. The Journal of Experimental Medicine 210 (10): 1993–2010.
Simpson, A., A. Custovic, R. Tepper, P. Graves, D.A. Stern, M. Jones, J. Hankinson, J.A. Curtin, J. Wu, M. Blekic, B.K. Bukvic, N. Aberle, S. Marinho, D. Belgrave, W.J. Morgan, and F.D. Martinez. 2012. Genetic variation in vascular endothelial growth factor-a and lung function. American Journal of Respiratory and Critical Care Medicine 185 (11): 1197–1204.
This study was supported by the Natural Science Foundation of China (no. 81770032) and Natural Science Foundation of Anhui Province (no. 1708085QH173).
Conflict of Interest
The authors declare that they have no conflict of interest.
All animal experiments described in this study were approved by the Animal Care and Use Committee of Anhui Medical University.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shen, Q., Wu, L., Wei, C. et al. Sevoflurane Prevents Airway Remodeling via Downregulation of VEGF and TGF-β1 in Mice with OVA-Induced Chronic Airway Inflammation. Inflammation 42, 1015–1022 (2019). https://doi.org/10.1007/s10753-019-00963-w
- airway inflammation
- airway remodeling